
Emily Niehaus
@emilyniehaus4
ID fellow @DukeAdultID. Residency @UofUHealth, MD/MPH from @EmoryMedicine. Always an Eph @WilliamsCollege.
ID: 1470217265702342658
13-12-2021 02:21:40
21 Tweet
56 Takipçi
117 Takip Edilen

Consult❓:“can I safely discharge a patient with a substance use disorder home with a PICC?” The inimitable Josh Barocas, MD and I have some thoughts: a [ahem, very long] 🧵 on our Curbside Consult in NEJM Evidence today. 1/15






Jonathan Ryder, MD Daniel Griffin MD PhD Infectious Disease Puscast Febrile Nico Cortes-Penfield MD FACP FIDSA 🦴💊 Geno Tai MD Also the next episode is Ortho ID 🦴too featuring the wonderful ⭐s Emily Niehaus and Laura Certain, MD, PhD

@swinndong Jonathan Ryder, MD Daniel Griffin MD PhD Infectious Disease Puscast Febrile Nico Cortes-Penfield MD FACP FIDSA 🦴💊 Geno Tai MD Emily Niehaus It was so fun to record a Febrile episode! Thanks @swinndong for hosting and to Emily Niehaus for putting together a great case. It was fun!

🔥☠️Check out our 50th episode out now: Bad to the Bone! 🦴Emily Niehaus & Laura Certain, MD, PhD take on the challenging topic of vertebral osteomyelitis +/- hardware! 👂Subscribe anywhere🎙️are found febrilepodcast.captivate.fm/listen #IDTwitter #IDMedEd #OrthoID



The University of Utah adult infectious diseases fellowship program has open positions! Come live and work in beautiful Salt Lake City with amazing faculty Laura Certain, MD, PhD Paloma F Cariello, MD, MPH 👩🏻⚕️👩🏻🏫🇧🇷🇺🇸 Emily Sydnor Spivak Daniel T Leung University of Utah Health and our fantastic (twitterless) PD Adrienne Carey!




🔥 Fresh out the oven 🔥 Updated 2023 Duke-ISCVID criteria for infective endocarditis from @VanceFowler5 and colleagues just published in Clinical Infectious Diseases 🫀🦠🩺#idtwitter #endocarditis academic.oup.com/cid/advance-ar…

#IDTwitter: Excited to announce that we have some new, open-access, peer-reviewed #IDChalkTalks from the IDSA Medical Education Community of Practice. These are ready-to-go, mini-lectures that are perfect for teaching in the clinical setting. Great for new fellows/trainees on service. idsame.notion.site/ID-Chalk-Talks…

Some thoughts on the biggest news out of #IAS2023, which was undoubtedly the REPRIEVE Trial -- and what it implies about the staggering success of HIV treatment that the most important HIV clinical trial in years involves a *statin*! Think about that ... blogs.jwatch.org/hiv-id-observa…


Original Article: Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women (PURPOSE 1) nej.md/3zRElVj Editorial: The Real PURPOSE of PrEP — Effectiveness, Not Efficacy nej.md/3Yj3LW3 #AIDS2024 | IAS - the International AIDS Society

